By David Williamson | More Articles May 31, 2012 | <\/p>\n
The following video is part of our \"Motley Fool Conversations\" series, in which health care editor\/analyst David Williamson discusses topics across the investing world. <\/p>\n
In today's edition, we put the three health care components of the Dow head to head to determine which is the best stock. Will it be highly diversified Johnson & Johnson, radically revamping Pfizer, or lurking big pharma member Merck? The answer may surprise you. <\/p>\n
Health care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health care company that he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report \"Discover the Next Rule-Breaking Multibagger.\"Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free. <\/p>\n
Please enable JavaScript to view this video. <\/p>\n<\/p>\n
Read more here:<\/p>\n
Dow Health Care Smackdown<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" By David Williamson | More Articles May 31, 2012 | The following video is part of our \"Motley Fool Conversations\" series, in which health care editor\/analyst David Williamson discusses topics across the investing world. In today's edition, we put the three health care components of the Dow head to head to determine which is the best stock. Will it be highly diversified Johnson & Johnson, radically revamping Pfizer, or lurking big pharma member Merck? Continue reading